BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Company Overview - BioCryst Pharmaceuticals (BCRX) is expected to report a quarterly loss of $0.23 per share, reflecting a year-over-year change of +17.9% [2] - Revenues are anticipated to be $85.6 million, which is a 24.5% increase from the same quarter last year [2] - The Most Accurate Estimate for BioCryst is higher than the Zacks Consensus Estimate, indicating a bullish sentiment among analysts [5] Earnings Expectations - The upcoming earnings report is scheduled for May 6, and the stock price may react positively if actual results exceed expectations [1] - The consensus EPS estimate has been revised 2.86% lower over the last 30 days, suggesting a reassessment of earnings expectations by analysts [2] - BioCryst has an Earnings ESP of +11.11%, which suggests a likelihood of beating the consensus EPS estimate [5][6] Historical Performance - In the last reported quarter, BioCryst was expected to post a loss of $0.24 per share but actually reported a loss of $0.28, resulting in a surprise of -16.67% [7] - Over the past four quarters, BioCryst has beaten consensus EPS estimates three times [7] Industry Context - In the Zacks Medical - Drugs industry, Zoetis (ZTS) is expected to post earnings of $1.35 per share for the same quarter, indicating a year-over-year change of +3.1% [9] - Zoetis's revenue is projected to be $2.14 billion, up 7% from the previous year [9] - The consensus EPS estimate for Zoetis has been revised 0.1% lower, and it has an Earnings ESP of 0.23% combined with a Zacks Rank of 4 (Sell), making predictions about beating the consensus EPS estimate challenging [9]